摘要
目的:分析大剂量静脉用人血丙种球蛋白(简称HDIVIG)静滴在急性特发性血小板减少性紫癜(简称ITP)治疗中的近期疗效,判断其使用价值。方法:回顾性分析2006年2月～2010年2月在本科住院的急性ITP患儿80例的临床治疗资料作为丙球组,早期应用HDIVIG静滴400mg/(kg·d),3～5d治疗,选择本院同期应用常规治疗的ITP患儿80例作为对照组。观察患儿出血症状控制、血小板开始上升时间、血小板达正常时间及住院天数。结果:丙球组80例患者中72例有效,有效率为90.0%,对照组80例患者中64例有效,有效率为80.0%,两组比较,差异有统计学意义(χ2=6.298,P<0.05)。结论:HDIVIG治疗是一种安全、有效的治疗方法,值得在伴有严重出血的ITP患者中推广使用。
Objective： To analyze the short-term curative effects of high-dose intravenous human immunoglobulin （HDIVIG） intravenous drip in the treatment of infantile idiopathic thrombocytopenic purpura （ITP） and determine its value. Methods： Clinical data of 80 children with acute ITP were given the early treatment of HDIVIG intravenous drip 400 mg/（kg·d）, 3-5 days, hospitalized in our department from February 2006 to February 2010 were analyzed retrospectively. 80 children with ITP who were given the conventional treatment in our hospital in the corresponding period, were selected as the control group. Bleeding symptom control, start time of platelets rising, time of platelets normalization and hospital stays of the children were observed. Results： 80 patients of the immunoglobulin group 72 cases were effective and the effective rate was 90.0% while 80 patients of the control group 64 cases were effective and the effective rate was 80.0%, with significant differences between the two groups （χ2=6.298, P0.05）. Conclusion： HDIVIG is a safe and effective treatment method, be worthy of promotion and application among patients with ITP accompanied by severe bleeding.
出处
《中国当代医药》
2011年第30期50-51,共2页
China Modern Medicine
